Hidechika Okada
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hidechika Okada has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
Noriko Okada
Department of Molecular Biology Nagoya City University Graduate School of Medical Sciences Aichi Nagoya 467‐8601 Japan
11 shared publicationsWilliam Campbell
Choju Medical Institute, Fukushimura Hospital, Toyohashi, Japan
5 shared publicationsHiroyasu Akatsu
Department of Molecular Biology Nagoya City University Graduate School of Medical Sciences Aichi Nagoya 467‐8601 Japan
3 shared publications- Noriko Okada
Department of Biodefense; Nagoya City University Graduate School of Medical Sciences; Aichi Nagoya 467-8601 Japan
3 shared publications - Dániel Érces
Sebészeti Műtéttani Intézet, Szegedi Tudományegyetem6720 Szeged, Szőkefalvi-Nagy Béla u. 6
2 shared publications - Gabriella Varga
Institute for Surgical Research, University of Szeged, Hungary
2 shared publications
Latest Publications
- Open Access
- 1 December 2013
- Published by Elsevier in Life Sciences
- Vol. 93 (25) , e69
Complement C5a antagonism is associated with reduced big-endothelin level after experimental cardiac tamponade
- 1 December 2013
- Published by Elsevier in Life Sciences
- Vol. 93 (25) , e69
Open AccessComplement C5a antagonism is associated with reduced big-endothelin level after experimental cardiac tamponade
- Open Access
- 1 December 2013
- Published by Elsevier in Life Sciences
- Vol. 93 (25-26) , e38
The anti-inflammatory effects of endothelin-a receptor antagonism during hyperdy/INS;namic sepsis in rats
- 1 December 2013
- Published by Elsevier in Life Sciences
- Vol. 93 (25-26) , e38
Open AccessThe anti-inflammatory effects of endothelin-a receptor antagonism during hyperdy/INS;namic sepsis in rats
- 31 October 2008
- Published by Elsevier in Molecular Immunology
- Vol. 45 (16) , 4113
C5a anaphylatoxin inhibitor suppresses a lethal cytokine storm in monkeys injected with LPS
- 31 October 2008
- Published by Elsevier in Molecular Immunology
- Vol. 45 (16) , 4113
C5a anaphylatoxin inhibitor suppresses a lethal cytokine storm in monkeys injected with LPS
- 1 April 2003
- Published by Wiley in Microbiology and Immunology
- Vol. 47 (4) , 295-300
Preferential Detection of Pro‐Carboxypeptidase R by Enzyme‐Linked Immunosorbent Assay
We generated two monoclonal antibodies (mAbs), 2A16 and 10G1, against pro‐carboxypeptidase R (proCPR), also known as thrombin activatable fibrinolysis inhibitor (TAFI). By use of these mAbs, we developed a sandwich enzyme‐linked immunosorbent assay (ELISA) system to detect proCPR. Since the amount of the antigen detectable by the ELISA was essentially the same in fresh plasma and serum incubated at 37 C for 1 hr, we concluded that the ELISA system detected not only proCPR, but also inactivated CPR generated from proCPR. However, an appreciable amount of proCPR remained unactivated in serum. For extensive activation of proCPR in plasma, thrombin and thrombomodulin complexes (T‐TM) can be used together with CaCl2. Following extensive conversion of proCPR to CPR by T‐TM and CaCl2, converting plasma to serum (T‐TM serum), antigenicity became undetectable by ELISA. Further analysis revealed that 2A16 reacts only with proCPR although 10G1 reacts with proCPR, active CPR and inactivated CPR. Therefore, we concluded that the ELISA system preferentially detects proCPR and not CPR. Our sandwich ELISA system utilizing 2A16 and 10G1 provides a suitable method for detecting proCPR and can be used to determine levels of proCPR in plasma samples from patients.
- 1 April 2003
- Published by Wiley in Microbiology and Immunology
- Vol. 47 (4) , 295-300
Preferential Detection of Pro‐Carboxypeptidase R by Enzyme‐Linked Immunosorbent Assay
We generated two monoclonal antibodies (mAbs), 2A16 and 10G1, against pro‐carboxypeptidase R (proCPR), also known as thrombin activatable fibrinolysis inhibitor (TAFI). By use of these mAbs, we developed a sandwich enzyme‐linked immunosorbent assay (ELISA) system to detect proCPR. Since the amount of the antigen detectable by the ELISA was essentially the same in fresh plasma and serum incubated at 37 C for 1 hr, we concluded that the ELISA system detected not only proCPR, but also inactivated CPR generated from proCPR. However, an appreciable amount of proCPR remained unactivated in serum. For extensive activation of proCPR in plasma, thrombin and thrombomodulin complexes (T‐TM) can be used together with CaCl2. Following extensive conversion of proCPR to CPR by T‐TM and CaCl2, converting plasma to serum (T‐TM serum), antigenicity became undetectable by ELISA. Further analysis revealed that 2A16 reacts only with proCPR although 10G1 reacts with proCPR, active CPR and inactivated CPR. Therefore, we concluded that the ELISA system preferentially detects proCPR and not CPR. Our sandwich ELISA system utilizing 2A16 and 10G1 provides a suitable method for detecting proCPR and can be used to determine levels of proCPR in plasma samples from patients.
- Open Access
- 1 February 2002
- Published by Wiley in Microbiology and Immunology
- Vol. 46 (2) , 115-117
Effect of Anticoagulants in Colorimetric Assay for Basic Carboxypeptidases
Carboxypeptidases (CP) in plasma and sera serve as regulators of anaphylatoxins such as C3a and C5a. The activity of CP can be measured by determining hippuric acid after cleavage of the small synthetic substrate hippuryl‐l‐arginine. Although a colorimetric assay is convenient for determining hippuric acid generated by CP, we noticed that some anticoagulants, such as citrate, interfere with the color development of the reagents used. EDTA and heparin provide an appropriate value. EGTA used as anticoagulant also provides an appropriate value. Therefore, concentration of citrate in samples should be controlled to be constant for background subtraction.
- 1 February 2002
- Published by Wiley in Microbiology and Immunology
- Vol. 46 (2) , 115-117
Open AccessEffect of Anticoagulants in Colorimetric Assay for Basic Carboxypeptidases
Carboxypeptidases (CP) in plasma and sera serve as regulators of anaphylatoxins such as C3a and C5a. The activity of CP can be measured by determining hippuric acid after cleavage of the small synthetic substrate hippuryl‐l‐arginine. Although a colorimetric assay is convenient for determining hippuric acid generated by CP, we noticed that some anticoagulants, such as citrate, interfere with the color development of the reagents used. EDTA and heparin provide an appropriate value. EGTA used as anticoagulant also provides an appropriate value. Therefore, concentration of citrate in samples should be controlled to be constant for background subtraction.
- Open Access
- 1 February 2002
- Published by Wiley in Microbiology and Immunology
- Vol. 46 (2) , 131-134
Inactivation of C3a and C5a Octapeptides by Carboxypeptidase R and Carboxypeptidase N
Pro‐carboxypeptidase R (proCPR), also known as thrombin‐activatable fibrinolysis inhibitor (TAFI), precursor of carboxypeptidase U and plasma carboxypeptidase B is present in plasma and following activation by thrombin/thrombomodulin and/or plasmin can remove arginine from the carboxyterminal of C3a and C5a. We have shown that this enzyme can remove terminal arginine from the C5a octapeptide much more efficiently than the classical anaphylatoxin inactivator, carboxypeptidase N (CPN). Since we have previously demonstrated that proCPR is significantly upregulated in the inflammatory state, this enzyme would appear to significantly contribute to the inactivation of C5a, the most potent of the complement derived anaphylatoxins.
- 1 February 2002
- Published by Wiley in Microbiology and Immunology
- Vol. 46 (2) , 131-134
Open AccessInactivation of C3a and C5a Octapeptides by Carboxypeptidase R and Carboxypeptidase N
Pro‐carboxypeptidase R (proCPR), also known as thrombin‐activatable fibrinolysis inhibitor (TAFI), precursor of carboxypeptidase U and plasma carboxypeptidase B is present in plasma and following activation by thrombin/thrombomodulin and/or plasmin can remove arginine from the carboxyterminal of C3a and C5a. We have shown that this enzyme can remove terminal arginine from the C5a octapeptide much more efficiently than the classical anaphylatoxin inactivator, carboxypeptidase N (CPN). Since we have previously demonstrated that proCPR is significantly upregulated in the inflammatory state, this enzyme would appear to significantly contribute to the inactivation of C5a, the most potent of the complement derived anaphylatoxins.
- 1 January 2001
- Published by Wiley in Microbiology and Immunology
- Vol. 45 (1) , 101-108
Elimination of Latently HIV‐1‐Infected Cells by Lymphoblasts Armed with Bifunctional Antibody
The Fab′ fragment of a monoclonal antibody (mAb) to CD3 and the F(ab′)2 fragment of a mAb to human immunodeficiency virus 1 (HIV‐1) gp41 were combined to generate a bifunctional antibody (BFA). The mAb to gp41 (IV1‐4G6) has previously been shown to react with a number of HIV‐1 strains and T‐lymphoblastoid cells (TLBC) armed with the BFA (BFA‐TLBC) effectively inhibited HIV‐1 in primarily cultured lymphoblasts infected with the clinically isolated virus which was reactive to the mAb. Although BFA‐TLBC could not cause cytolysis of 51Cr‐labeled latently infected cells (OM‐10.1) in 6 hr incubation, cocultivation of OM‐10.1 cells with BFA‐TLBC for 3 days or more eliminated the latently infected cells making the cells susceptible to BFA‐TLBC. Therefore, BFA‐TLBC may be beneficial for HIV‐infected patients in eradicating latently infected cells which can not be eliminated even with highly active antiretroviral therapy (HAART).
- 1 January 2001
- Published by Wiley in Microbiology and Immunology
- Vol. 45 (1) , 101-108
Elimination of Latently HIV‐1‐Infected Cells by Lymphoblasts Armed with Bifunctional Antibody
The Fab′ fragment of a monoclonal antibody (mAb) to CD3 and the F(ab′)2 fragment of a mAb to human immunodeficiency virus 1 (HIV‐1) gp41 were combined to generate a bifunctional antibody (BFA). The mAb to gp41 (IV1‐4G6) has previously been shown to react with a number of HIV‐1 strains and T‐lymphoblastoid cells (TLBC) armed with the BFA (BFA‐TLBC) effectively inhibited HIV‐1 in primarily cultured lymphoblasts infected with the clinically isolated virus which was reactive to the mAb. Although BFA‐TLBC could not cause cytolysis of 51Cr‐labeled latently infected cells (OM‐10.1) in 6 hr incubation, cocultivation of OM‐10.1 cells with BFA‐TLBC for 3 days or more eliminated the latently infected cells making the cells susceptible to BFA‐TLBC. Therefore, BFA‐TLBC may be beneficial for HIV‐infected patients in eradicating latently infected cells which can not be eliminated even with highly active antiretroviral therapy (HAART).
- Open Access
- 1 August 2000
- Published by Wiley in Microbiology and Immunology
- Vol. 44 (8) , 719-728
Molecular Cloning and Partial Characterization of Rat Procarboxypeptidase R and Carboxypeptidase N
Carboxypeptidase R (EC 3.4.17.20) (CPR) and carboxypeptidase N (EC 3.4.17.3) (CPN) cleave carboxy‐terminal arginine or lysine residues from biologically active peptides such as kinins or anaphylatoxins in the circulation thereby regulating their activities. Although CPN is present in a stable active form in plasma, CPR is generated from proCPR, a plasma zymogen, by proteolytic enzymes such as thrombin, thrombin‐thrombomodulin complex and plasmin. We have isolated rat proCPR and CPN cDNA clones which can induce enzymatic activities in culture supernatants of the transfected cells. mRNA of proCPR was detected only in rat liver by Northern hybridization and showed hepatocyte‐specific expression. Expression of proCPR mRNA was enhanced following LPS injection, indicating that proCPR production is increased under inflammatory conditions.
- 1 August 2000
- Published by Wiley in Microbiology and Immunology
- Vol. 44 (8) , 719-728
Open AccessMolecular Cloning and Partial Characterization of Rat Procarboxypeptidase R and Carboxypeptidase N
Carboxypeptidase R (EC 3.4.17.20) (CPR) and carboxypeptidase N (EC 3.4.17.3) (CPN) cleave carboxy‐terminal arginine or lysine residues from biologically active peptides such as kinins or anaphylatoxins in the circulation thereby regulating their activities. Although CPN is present in a stable active form in plasma, CPR is generated from proCPR, a plasma zymogen, by proteolytic enzymes such as thrombin, thrombin‐thrombomodulin complex and plasmin. We have isolated rat proCPR and CPN cDNA clones which can induce enzymatic activities in culture supernatants of the transfected cells. mRNA of proCPR was detected only in rat liver by Northern hybridization and showed hepatocyte‐specific expression. Expression of proCPR mRNA was enhanced following LPS injection, indicating that proCPR production is increased under inflammatory conditions.
- Open Access
- 15 July 2000
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 165 (2) , 1053-1058
Pro-Carboxypeptidase R is an Acute Phase Protein in the Mouse, Whereas Carboxypeptidase N Is Not
Carboxypeptidase R (EC 3.4.17.20; CPR) and carboxypeptidase N (EC 3.4.17.3; CPN) cleave carboxyl-terminal arginine and lysine residues from biologically active peptides such as kinins and anaphylatoxins, resulting in regulation of their biological activity. Human proCPR, also known as thrombin-activatable fibrinolysis inhibitor, plasma pro-carboxypeptidase B, and pro-carboxypeptidase U, is a plasma zymogen activated during coagulation. CPN, however, previously termed kininase I and anaphylatoxin inactivator, is present in a stable active form in plasma. We report here the isolation of mouse proCPR and CPN cDNA clones that can induce their respective enzymatic activities in culture supernatants of transiently transfected cells. Potato carboxypeptidase inhibitor can inhibit carboxypeptidase activity in culture medium of mouse proCPR-transfected cells. The expression of proCPR mRNA in murine liver is greatly enhanced following LPS injection, whereas CPN mRNA expression remains unaffected. Furthermore, the CPR activity in plasma increased 2-fold at 24 h after LPS treatment. Therefore, proCPR can be considered a type of acute phase protein, whereas CPN is not. An increase in CPR activity may facilitate rapid inactivation of inflammatory mediators generated at the site of Gram-negative bacterial infection and may consequently prevent septic shock. In view of the ability of proCPR to also inhibit fibrinolysis, an excess of proCPR induced by LPS may contribute to hypofibrinolysis in patients suffering from disseminated intravascular coagulation caused by sepsis.
- 15 July 2000
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 165 (2) , 1053-1058
Open AccessPro-Carboxypeptidase R is an Acute Phase Protein in the Mouse, Whereas Carboxypeptidase N Is Not
Carboxypeptidase R (EC 3.4.17.20; CPR) and carboxypeptidase N (EC 3.4.17.3; CPN) cleave carboxyl-terminal arginine and lysine residues from biologically active peptides such as kinins and anaphylatoxins, resulting in regulation of their biological activity. Human proCPR, also known as thrombin-activatable fibrinolysis inhibitor, plasma pro-carboxypeptidase B, and pro-carboxypeptidase U, is a plasma zymogen activated during coagulation. CPN, however, previously termed kininase I and anaphylatoxin inactivator, is present in a stable active form in plasma. We report here the isolation of mouse proCPR and CPN cDNA clones that can induce their respective enzymatic activities in culture supernatants of transiently transfected cells. Potato carboxypeptidase inhibitor can inhibit carboxypeptidase activity in culture medium of mouse proCPR-transfected cells. The expression of proCPR mRNA in murine liver is greatly enhanced following LPS injection, whereas CPN mRNA expression remains unaffected. Furthermore, the CPR activity in plasma increased 2-fold at 24 h after LPS treatment. Therefore, proCPR can be considered a type of acute phase protein, whereas CPN is not. An increase in CPR activity may facilitate rapid inactivation of inflammatory mediators generated at the site of Gram-negative bacterial infection and may consequently prevent septic shock. In view of the ability of proCPR to also inhibit fibrinolysis, an excess of proCPR induced by LPS may contribute to hypofibrinolysis in patients suffering from disseminated intravascular coagulation caused by sepsis.
- Open Access
- 1 May 2000
- Published by Wiley in Microbiology and Immunology
- Vol. 44 (5) , 405-410
The IgM Antibody Level against Ganglioside GM2 Correlates to the Disease Status of HIV-1-Infected Patients
HIV‐1 infection induces the expression of high level of GM2 ganglioside on infected cells and IgM antibody (Ab) against GM2 can cause complement (C)‐mediated cytolysis of HIV‐1‐infected cells. Since GM2 is immunogenic in human, we proposed that an anti‐GM2 IgM Ab may be produced by some HIV‐1‐infected patients and the titer of this Ab might provide some insight into the progress of the disease. On this premise, the amount of IgM Ab against GM2 was determined in 124 HIV‐1‐infected patients and 111 seronegative donors. As expected, the anti‐GM2 IgM Ab titers of the patients was significantly higher than that of the seronegative donors while the total IgM levels remained unchanged. In addition, we determined the CD4+ cell count and the HIV‐RNA load in the HIV‐1‐infected patients. The results showed a positive correlation between the anti‐GM2 IgM Ab titer and CD4+ cell count but a negative correlation between the anti‐GM2 IgM Ab titer and HIV‐RNA load. These suggest that anti‐GM2 IgM Ab induced and/or enhanced by HIV‐1 infection causes C‐mediated cytolysis of HIV‐1‐infected cells in vivo to a certain extent, and may help lower the plateau level of the HIV‐RNA load. Therefore, the amount of IgM Ab against GM2 may be related to the prognosis of HIV‐1 infected patients.
- 1 May 2000
- Published by Wiley in Microbiology and Immunology
- Vol. 44 (5) , 405-410
Open AccessThe IgM Antibody Level against Ganglioside GM2 Correlates to the Disease Status of HIV-1-Infected Patients
HIV‐1 infection induces the expression of high level of GM2 ganglioside on infected cells and IgM antibody (Ab) against GM2 can cause complement (C)‐mediated cytolysis of HIV‐1‐infected cells. Since GM2 is immunogenic in human, we proposed that an anti‐GM2 IgM Ab may be produced by some HIV‐1‐infected patients and the titer of this Ab might provide some insight into the progress of the disease. On this premise, the amount of IgM Ab against GM2 was determined in 124 HIV‐1‐infected patients and 111 seronegative donors. As expected, the anti‐GM2 IgM Ab titers of the patients was significantly higher than that of the seronegative donors while the total IgM levels remained unchanged. In addition, we determined the CD4+ cell count and the HIV‐RNA load in the HIV‐1‐infected patients. The results showed a positive correlation between the anti‐GM2 IgM Ab titer and CD4+ cell count but a negative correlation between the anti‐GM2 IgM Ab titer and HIV‐RNA load. These suggest that anti‐GM2 IgM Ab induced and/or enhanced by HIV‐1 infection causes C‐mediated cytolysis of HIV‐1‐infected cells in vivo to a certain extent, and may help lower the plateau level of the HIV‐RNA load. Therefore, the amount of IgM Ab against GM2 may be related to the prognosis of HIV‐1 infected patients.